{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-002184","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2025-01-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.355380+00:00","generated_at":"2026-05-27T05:49:37.920506+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Allarity Therapeutics reaches $2.5M SEC settlement over Dovitinib disclosure issues","bullets":["Agreed in principle with SEC to pay $2.5M civil penalty and consent to cease-and-desist order for non-scienter securities law violations.","Investigation concerns company's disclosures about FDA meetings for Dovitinib NDA submitted in 2021.","Three former officers received Wells Notices; company has accrued ~$1.8M for their legal fees, with insurance coverage subject to $3.5M retention.","Settlement is subject to final language and SEC approval; company must cooperate in any future SEC litigation."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-002184","json":"https://secwatch.observer/filing/0001437749-25-002184.json","markdown":"https://secwatch.observer/filing/0001437749-25-002184.md","text":"https://secwatch.observer/filing/0001437749-25-002184.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000143774925002184/0001437749-25-002184-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000143774925002184/allr20250117_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T05:49:37.920506+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}